Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

A Study to Investigate THT140, in Subjects With Advanced Solid Tumors and Lymphoma

16 novembre 2026 aggiornato da: Tethra Biosciences Inc.

A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of THT140, an Oral PLK1 Inhibitor, in Subjects With Advanced Solid Tumors and Lymphoma

This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, pharmacogenomics, and efficacy of THT40 administered orally daily. This study consists of Phase 1 and Phase 2 components in subjects with advanced solid tumors and lymphoma with a focus on tumors with ARID1A and similar mutations who have progressed despite having received standard therapy or for whom no standard therapy exists.

Panoramica dello studio

Stato

Reclutamento

Intervento / Trattamento

Descrizione dettagliata

Phase 1 part of the study will consist of a dose-escalation and a dose-finding component. Phase 1 also includes expansion cohorts for subject with ARID1A and similar mutations.

Phase 2 will enroll subjects with locally advanced, recurrent, or metastatic, histologically confirmed advanced solid tumors or lymphoma, who have failed all standard therapies or for whom standard therapy does not exist, into 8 groups:

Group 1: Bladder cancer

Group 2: Breast cancer: Triple-negative breast cancer (TNBC)

Group 3: Lung cancer (non-small cell lung cancer [NSCLC] and small cell lung cancer [SCLC])

Group 4: Hepatocellular carcinoma (HCC) and biliary tract cancer (BTC)

Group 5: Metastatic colorectal cancer (mCRC) including KRAS-mutated mCRC

Group 6: B-cell lymphoma including diffuse large B-cell lymphoma (DLBCL)

Group 7: T-cell lymphoma (cutaneous T-cell lymphoma [CTCL] and peripheral T-cell lymphoma [PTCL])

Group 8: Basket cohort: tumor types that are suspected to have a related mechanism of action but are not included in previous groups including, esophageal, prostate, ovarian and pancreatic cancers

Tipo di studio

Interventistico

Iscrizione (Stimato)

330

Fase

  • Fase 2
  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

      • Seoul, Corea del Sud
        • Non ancora reclutamento
        • Seoul National University Hospital
        • Contatto:
      • Barcelona, Spagna
        • Non ancora reclutamento
        • Hospital Universitario Vall d'Hebron
        • Contatto:
    • New York
      • New York, New York, Stati Uniti, 10065
        • Reclutamento
        • Memorial Sloan Kettering Cancer Center (MSKCC)
        • Contatto:
    • Texas
      • Houston, Texas, Stati Uniti, 77030
        • Reclutamento
        • MD Anderson Cancer Center
        • Contatto:
    • Washington
      • Seattle, Washington, Stati Uniti, 98109
        • Reclutamento
        • Fred Hutchinson Cancer Center/ University of Washington
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Males or females aged ≥ 18 years.

  2. Subjects with histological- or cytological-confirmed, advanced cancer who have progressed on (or not been able to tolerate) standard therapy or for whom no standard anticancer therapy exists

    1. For Phase 1, all tumor types may be enrolled
    2. For Phase 2, subjects will be enrolled as per the study design section above
  3. ECOG performance status of 0-2.

  4. Subjects who relapsed post-autologous or post-allogeneic transplant are eligible. Post-transplant subjects must be without active fungal disease or significant acute graft-versus-host disease

  5. Women of childbearing potential (WOCBP) must have a negative pregnancy test (urine or serum) within 7 days prior to starting the study drug. Both males and females must agree to use effective birth control during the study (prior to the first dose and for 6 months after the last dose) if conception is possible during this interval.

  6. Subjects must be able to swallow and retain orally administered medication and not have any clinically significant GI abnormalities that may alter the absorption, such as malabsorption syndrome or major resection of the stomach or bowels.

  7. Able to agree to and sign the informed consent and to comply with the protocol.

Exclusion Criteria:

  1. Subjects with a history of brain metastases or who have signs/symptoms attributable to brain metastases and have not been assessed with radiologic imaging to rule out the presence of brain metastases. Subjects with treated brain metastases that are asymptomatic and have been clinically stable for at least 4 weeks will be eligible.

  2. Subjects who have not received vaccines for severe acute respiratory syndrome-corona virus-2 (SARS-COV-2) and have suspected signs and symptoms of the novel coronavirus infection (COVID-19) or have confirmed COVID-19.

  3. Subjects with a history of another primary malignancy, other than:

    1. In situ carcinomas, e.g., breast, cervix, and prostate
    2. Locally excised nonmelanoma skin cancer
    3. No evidence of disease from another primary cancer for 2 or more years and has not taken any anti-cancer treatment in 2 years.
  4. Any other clinically significant acute or chronic medical or psychiatric condition or any laboratory abnormality that may increase the risk associated with study drug administration or may interfere with the interpretation of study results.

  5. Diseases that significantly affect GI absorption of THT140.

  6. Subjects who have impaired cardiac function or clinically significant cardiac disease.

  7. Presence of active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or GI perforation within 6 months of enrollment

  8. Presence of an active infection requiring intravenous antibiotics

  9. Presence of known history of human immunodeficiency virus-1/2 with uncontrolled viral load and on medications that may interfere with metabolism

  10. Presence of active hepatitis B virus (HBV) or hepatitis C virus (HCV).

  11. Chemotherapy, biologic therapy, targeted therapy, immunotherapy, extended-field radiotherapy, or investigational agents within 5 half-lives or 3 weeks (whichever is shorter) prior to administration of first dose of study drug on Day 1 or have not recovered from the side effects of such therapy.

  12. Major surgery/surgical therapy for any cause within 4 weeks of the first dose

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione sequenziale
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Phase 1 Dose Escalation

Phase 1 = THT140 administered orally in escalating doses starting at 5mg QD M-F week 1 to 3 for 3 weeks of a 4 week cycle. Subsequent cohorts will escalate in dose and schedule until optimized phase 2 dose and schedule is achieved.

THT140 is a highly selective, orally- and intravenously- available, ATP-competitive inhibitor of PLK1.

Altri nomi:
  • Plogosertib
Sperimentale: Phase 2

Phase 2 = Recommended THT140 phase 2 dose and schedule administered orally in 28-day cycles.

THT140 is a highly selective, orally- and intravenously- available, ATP-competitive inhibitor of PLK1.

Altri nomi:
  • Plogosertib

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Maximum tolerated dose
Lasso di tempo: 6 months

The incidence rate of dose-limiting toxicities (first cycle only) at each dose level

6 months
Overall Response Rate (ORR)
Lasso di tempo: 18 months

Assessment of response criteria according to RESIST, Lugano or mSWAT.

18 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Adverse events
Lasso di tempo: 24 months

Type, frequency, and severity of adverse drug reactions

24 months
AUC
Lasso di tempo: 6 months

THT140 plasma concentrations

6 months
Cmax
Lasso di tempo: 6 months

THT140 plasma concentrations

6 months
Tmax
Lasso di tempo: 6 months

THT140 plasma concentrations

6 months
T1/2
Lasso di tempo: 6 months

THT140 plasma concentrations

6 months
Disease Control Rate
Lasso di tempo: 24 months

To evaluate the disease control rate (DCR) in subjects receiving THT140.

24 months
Duration of Response
Lasso di tempo: 24 months

To evaluate the duration of response (DOR) in subjects receiving THT140.

24 months
Progression-free Survival
Lasso di tempo: 24 months

To evaluate progression-free survival (PFS) in subjects receiving THT140.

24 months
Overall Survival
Lasso di tempo: 24 months

To evaluate overall survival (OS) in subjects receiving THT140.

24 months

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Pharmacodynamics
Lasso di tempo: 6 months

Pharmacodynamic response to THT140 will be assessed by mRNA sequencing of blood samples to determine differential expression of PLK1 target genes (including MYC, PLK1, CDKN1A) relative to baseline.

6 months
Pharmacogenomics
Lasso di tempo: 24 months

Genomic alterations will be assessed by next generation sequencing (NGS) at baseline and various time points during treatment with THT140 in order to investigate the relationship between genetic alterations in THT140 related pathways and response to THT140.

Parameters of genetic variations (DNA mutations) and copy number variations using plasma cell-free DNA derived from peripheral blood will be assessed.

24 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

14 aprile 2022

Completamento primario (Stimato)

1 novembre 2028

Completamento dello studio (Stimato)

1 maggio 2029

Date di iscrizione allo studio

Primo inviato

19 aprile 2022

Primo inviato che soddisfa i criteri di controllo qualità

27 aprile 2022

Primo Inserito (Effettivo)

3 maggio 2022

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

20 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

16 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi